Finally, our findings suggest that immunotherapy combined with anti‐CD200 drugs might be a promising therapeutic option for bladder cancer patients with high proportions of PD1hi CD200hi CD4+ exhausted T cells. Here, CD200 is linked to urinary bladder cancer.